Medical Microinstruments (MMI) raised $125 million in Series D financing to expand its Symani Surgical System and broaden microsurgery applications. The funding also supports development of an experimental approach for Alzheimer’s disease, extending the company’s focus beyond surgical platform growth. MMI’s Symani technology is designed to improve precision in minimally invasive procedures, and the new capital will be used to increase deployment and explore additional indications for robotic microsurgery. The financing highlights continued investor appetite for tool-and-platform plays that can migrate from procedure innovation into disease-area expansion. The Alzheimer’s component adds a research-forward dimension to a robotics-led story, even as the primary commercial value remains tied to surgical adoption.